Jonathan Brammer
Clinical trials sponsored by Jonathan Brammer, explained in plain language.
-
New drug may keep T-Cell lymphoma at bay after transplant
Disease control Recruiting nowThis phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphoma…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for rare leukemia: ruxolitinib trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug ruxolitinib can shrink tumors in 30 adults with T-cell large granular lymphocyte leukemia, a rare blood cancer. Ruxolitinib works by blocking enzymes that cancer cells need to grow. The study will measure how many patients respond to trea…
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC